Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.91 and last traded at $3.09, with a volume of 1,488,941 shares trading hands. The stock had previously closed at $3.37.

A number of analysts have issued reports on AVXL shares. FBR & Co reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Wednesday. Maxim Group reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Monday, June 6th. Finally, Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.

The company’s market capitalization is $111.06 million. The company has a 50-day moving average price of $5.63 and a 200 day moving average price of $4.88.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. On average, equities analysts forecast that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.